Age Related Macular Degeneration Amd Market Size, Share, Industry Trends and Forecast to 2033
This report provides a comprehensive analysis of the Age Related Macular Degeneration (AMD) market, covering the market size, growth forecasts, industry trends, and regional insights for the period 2023-2033.
| Metric | Value |
|---|---|
| Study Period | 2023 - 2033 |
| 2023 Market Size | $8.00 Billion |
| CAGR (2023-2033) | 7.2% |
| 2033 Market Size | $16.35 Billion |
| Top Companies | Regeneron Pharmaceuticals, Inc., Novartis AG, Roche Holdings AG, Bayer AG, Alcon Inc. |
| Last Modified Date | 15 Nov 2024 |
Age Related Macular Degeneration Amd Market Report (2023 - 2033)
Age Related Macular Degeneration Amd Market Overview
What is the Market Size & CAGR of Age Related Macular Degeneration Amd market in 2023?
Age Related Macular Degeneration Amd Industry Analysis
Age Related Macular Degeneration Amd Market Segmentation and Scope
Request a custom research report for industry.
Age Related Macular Degeneration Amd Market Analysis Report by Region
Europe Age Related Macular Degeneration Amd Market Report:
Europe is projected to grow from a market size of $2.37 billion in 2023 to $4.84 billion by 2033. The growth is attributed to an aging population, high disposable incomes, and increased focus on eye health.Asia Pacific Age Related Macular Degeneration Amd Market Report:
The Asia Pacific region had a market valuation of $1.47 billion in 2023, projected to grow to $3.00 billion by 2033. Factors driving growth include increased healthcare expenditure, rising awareness of eye health issues, and a significant geriatric population.North America Age Related Macular Degeneration Amd Market Report:
North America holds a significant market share, valued at $2.99 billion in 2023, forecasted to grow to $6.11 billion by 2033. This growth is driven by advanced healthcare infrastructure, high awareness levels, and substantial R&D investments.South America Age Related Macular Degeneration Amd Market Report:
In South America, the AMD market was valued at $0.28 billion in 2023 and expected to reach $0.57 billion by 2033. Growth factors include increasing healthcare access and improving economic conditions which enhance overall patient care.Middle East & Africa Age Related Macular Degeneration Amd Market Report:
The market in the Middle East and Africa stood at $0.90 billion in 2023 and is expected to grow to $1.83 billion by 2033, driven by improving healthcare services and rising awareness of health conditions.Request a custom research report for industry.
Age Related Macular Degeneration Amd Market Analysis By Disease Type
Global Age-Related Macular Degeneration (AMD) Market, By Disease Type Market Analysis (2023 - 2033)
The AMD market segmentation by disease type highlights Dry AMD commanding a significant market share with a size of $6.54 billion in 2023, expected to grow to $13.37 billion by 2033, holding steady at 81.78% market share. Wet AMD, while smaller, is projected to grow from $1.46 billion to $2.98 billion, maintaining an 18.22% share.
Age Related Macular Degeneration Amd Market Analysis By Treatment Type
Global Age-Related Macular Degeneration (AMD) Market, By Treatment Type Market Analysis (2023 - 2033)
Pharmaceuticals represent the largest share in treatment types, valued at $5.36 billion in 2023, expected to reach $10.95 billion by 2033 with a 66.97% market share. Surgical procedures and nutritional supplements are also crucial, with sizes expected to grow from $1.67 billion to $3.41 billion and $0.98 billion to $2.00 billion, respectively.
Age Related Macular Degeneration Amd Market Analysis By Distribution Channel
Global Age-Related Macular Degeneration (AMD) Market, By Distribution Channel Market Analysis (2023 - 2033)
The distribution channel segment indicates that Hospital Pharmacies hold a significant market share of $5.36 billion in 2023 and is projected to double to $10.95 billion by 2033. Retail and online pharmacies follow, with estimated values growing considerably within the same period.
Age Related Macular Degeneration Amd Market Analysis By Stage Of Disease
Global Age-Related Macular Degeneration (AMD) Market, By Stage of Disease Market Analysis (2023 - 2033)
The segmentation by disease stage reveals that the Early Stage holds a substantial market size of $5.36 billion in 2023, anticipated to grow to $10.95 billion. The Intermediate and Advanced Stages are also growing segments, driven by the increasing prevalence of AMD.
Age Related Macular Degeneration Amd Market Trends and Future Forecast
Request a custom research report for industry.
Global Market Leaders and Top Companies in Age Related Macular Degeneration Amd Industry
Regeneron Pharmaceuticals, Inc.:
A leading player in the AMD market known for its innovative treatments and high-quality research, particularly in developing drug therapies for Wet AMD.Novartis AG:
A global healthcare leader that offers a range of treatments for AMD and is heavily involved in research, focused on improving patient outcomes through innovative therapies.Roche Holdings AG:
Notable for its significant contributions towards advancing AMD treatment solutions, Roche emphasizes precision medicine in its offerings.Bayer AG:
Bayer is recognized for its extensive range of products related to eye diseases, especially for its commitment to research and development in AMD treatments.Alcon Inc.:
A global leader in eye care, Alcon provides a range of surgical and pharmaceutical products targeting AMD, committed to enhancing patient care.We're grateful to work with incredible clients.
